Home - Products - Angiogenesis - PDGFR - PDGFR Tyrosine Kinase Inhibitor III

PDGFR Tyrosine Kinase Inhibitor III

CAS No. 205254-94-0

PDGFR Tyrosine Kinase Inhibitor III( —— )

Catalog No. M35325 CAS No. 205254-94-0

PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III) is a multikinase inhibitor that inhibits PDGFR, EGFR, FGFR, PKA, and PKC and can be used for research on amyotrophic lateral sclerosis .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 44 In Stock
5MG 42 In Stock
10MG 67 In Stock
25MG 155 In Stock
50MG 220 In Stock
100MG 319 In Stock
200MG 436 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    PDGFR Tyrosine Kinase Inhibitor III
  • Note
    Research use only, not for human use.
  • Brief Description
    PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III) is a multikinase inhibitor that inhibits PDGFR, EGFR, FGFR, PKA, and PKC and can be used for research on amyotrophic lateral sclerosis .
  • Description
    PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    PDGFR
  • Recptor
    PDGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    205254-94-0
  • Formula Weight
    485.53
  • Molecular Formula
    C27H27N5O4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (205.96 mM; Ultrasonic (<60°C)
  • SMILES
    O(C)C1=CC=2C(=NC=NC2C=C1OC)N3CCN(C(NC4=CC=C(OC5=CC=CC=C5)C=C4)=O)CC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Young-Min Lee. Compositions and methods for zika virus characterization and vaccine development. WO2019204654A1.
molnova catalog
related products
  • Rinucumab

    Rinucumab (REGN 2176) is an anti-platelet-derived growth factor (PDGF) IgG4-like monoclonal antibody that acts by binding to the PDGF-β receptor and can be used to study age-related macular degeneration.

  • Flumatinib mesylate

    Flumatinib mesylate is a selective inhibitor of c-Abl PDGFRβ and c-Kit effectively overcomes drug resistance of certain KIT mutants.

  • GF109203X

    GF109203X is a potent PKC inhibitor with IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ, respectively.